Skip to main content
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
- Author(s): Won, Brian;
- Mambetsariev, Isa;
- Salgia, Ravi
- et al.
Published Web Locationhttps://doi.org/10.1186/s12885-016-2636-z
BackgroundWe report the re-biopsied diagnosis of a patient with anaplastic lymphoma receptor tyrosine kinase (ALK)-positive lung adenocarcinoma successfully treated with ceritinib 450 mg/day taken with food following disease progression and gastrointestinal intolerance to crizotinib.
Case presentationA 74-year old female patient initially diagnosed with ALK-negative lung adenocarcinoma responded to initial standard chemotherapy. The patient was subsequently re-tested by next generation sequencing (NGS) and found to have ALK EIF2AK3-ALK fusion, and responded to crizotinib, but ultimately progressed and showed intolerance to this ALK inhibitor. She was then successfully treated with ceritinib 450 mg/day taken with food, has not suffered from any further gastrointestinal side-effects, and remains on ceritinib treatment after 12 months.
ConclusionsSecond-line ceritinib treatment, when administered at 450 mg/day with food, is both well tolerated and efficacious in a patient with previously treated lung adenocarcinoma who had discontinued crizotinib due to disease progression and gastrointestinal adverse effects (AEs).
For improved accessibility of PDF content, download the file to your device.